Eli Lilly will acquire AtaiBeckley for $6.75 per share plus up to $2.50 in contingent value rights, expanding its neuroscience pipeline.
Eli Lilly and Co will acquire AtaiBeckley Inc. in a deal valued at up to $3.8 billion, including $2.8 billion in upfront cash and potential milestone payments. The transaction offers $6.75 per share at closing, a 40% premium to AtaiBeckley’s 30-day volume-weighted average price through July 15, 2026.
AtaiBeckley’s pipeline includes BPL-003, an intranasal therapy for treatment-resistant depression with Breakthrough Therapy Designation. The acquisition strengthens Lilly’s neuroscience portfolio with therapies targeting synaptic connectivity, differing from traditional antidepressants.
Shareholders will receive contingent value rights worth up to $2.50 per share tied to clinical, regulatory, and commercial milestones for AtaiBeckley’s lead programs.